Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Sizheng Steven ZhaoLianne Kearsley-FleetAilsa BosworthKath Watsonnull nullKimmie L HyrichPublished in: Rheumatology (Oxford, England) (2022)
Many patients will eventually benefit after repeated trials of b/tsDMARD. Further research to improve treatment selection are needed to prevent prolonged trial and error approaches in some patients.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- study protocol
- disease activity
- systemic sclerosis
- systemic lupus erythematosus
- cancer therapy
- drug delivery
- combination therapy
- patient reported
- idiopathic pulmonary fibrosis
- interstitial lung disease
- drug induced